Cargando…
Efficacy and safety of PAC‐14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild‐to‐moderate atopic dermatitis: a phase IIb randomized trial
BACKGROUND: Transient receptor potential vanilloid subfamily, member 1 (TRPV1) may play an important role in pruritus and inflammation induction in atopic dermatitis (AD). The treatment effect of TRPV1 antagonist via topical application in patients with AD remains unknown. OBJECTIVES: To assess the...
Autores principales: | Lee, Y.W., Won, C.‐H., Jung, K., Nam, H.‐J., Choi, G., Park, Y.‐H., Park, M., Kim, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850419/ https://www.ncbi.nlm.nih.gov/pubmed/30623408 http://dx.doi.org/10.1111/bjd.17455 |
Ejemplares similares
-
Atopic dermatitis: a review of topical nonsteroid therapy
por: Papier, Ariana, et al.
Publicado: (2018) -
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022) -
Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment
por: Duan, M. Q., et al.
Publicado: (2023) -
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023) -
The Suppressive Effect of Mamiran Cream on Atopic Dermatitis-Like Skin Lesions In Vivo
por: Aierken, Kailibinuer, et al.
Publicado: (2021)